Protocol Ledger

NCT04888429 · Phase II · COMPLETED

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Interventional Phase II clinical trial protocol NCT04888429 sponsored by Qian Chu in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-19 Enrollment: 17 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04888429
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)17 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04888429
Protocol FieldVerified Registry Value
NCT IdentifierNCT04888429
Consolidated Lead SponsorQian Chu
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment17 participants (ACTUAL)
Registered Start Date2021-07-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI